FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hoerter Steven L.</u>					2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC AGIO						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS 88 SIDNEY STREET				07/	3. Date of Earliest Transaction (Month/Day/Year) 07/20/2018						X Officer (give title Other (specify below)  Chief Commercial Officer				
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execu Day/Year) if any		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)		d (A) or r. 3, 4 and	5. Amoun Securities Beneficia Owned Fo Reported	es Form ally (D) of following (I) (Ir	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code V	Amount	(A) or (D)	Price	Transacti (Instr. 3 a			instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year	Date, Transaction				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Performance share units	(1)	07/20/2018		A		15,000		(2)	(2)	Common Stock	15,000	\$0.00	15,000	D	

## **Explanation of Responses:**

- 1. Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The performance share units were originally granted on February 16, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

## Remarks:

/s/ William Cook, as Attorneyin-fact for Steven Hoerter

07/24/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.